Skip to content
Insider tapeFilings through Fri, Oct 9
Watchlist
TSHA

Taysha Gene Therapies (TSHA) stock: insider trades, news & valuation

Heavy selling
Close · Oct 9, 2026 $4.49 +1.4% on the day -10.2% over 12 months 52-week range $3.83 – $6.98

Share price and insider trades

TSHA closeInsider buyInsider sale
34567NovDecJan 2026FebMarAprMayJunJulAugSepOctSold $7,481 on 2026-02-04 · Kamran AlamSold $424,484 on 2026-01-26 · Kamran Alam, Sean P. Nolan, Sukumar NagendranSold $523,094 on 2025-11-28 · Sukumar NagendranSold $892,000 on 2026-04-10 · Sukumar NagendranSold $942,000 on 2026-01-12 · Sukumar NagendranSold $1,172,812 on 2025-12-01 · Sukumar NagendranSold $1,248,000 on 2026-07-10 · Sukumar NagendranSold $1,448,223 on 2026-01-23 · Kamran Alam, Sean P. Nolan, Sukumar Nagendran
Bought, 12 months$0
Sold, 12 months$6.7M
Insiders buying0
Insiders selling3

Taysha Gene Therapies insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 3 sold $6.7M of TSHA stock on the open market.

TSHA insider buying and selling by quarter

Open-market purchases (green, above the line) and sales (red, below), by trade date.

Q4 2025: $1.7M sold (2 trades)Q4 2025Q1 2026: $2.8M sold (8 trades)Q1 2026Q2 2026: $892K sold (1 trades)Q2 2026Q3 2026: $1.2M sold (1 trades)Q3 2026Q4 2026
QuarterBoughtPurchasesSoldSales
Q4 2026—0—0
Q3 2026—0$1.2M1
Q2 2026—0$892K1
Q1 2026—0$2.8M8
Q4 2025—0$1.7M2

Valuation, profit and volume

P/E (trailing)n/aSector median —
Market value— 
Profit margin—Revenue growth —
Volume vs. 50-day1.4×Last 5 sessions
Insiders' paper profit—On all tracked purchases —

Summary

Over the past 12 months, 0 Taysha Gene Therapies, Inc. insiders reported open-market purchases totaling $0, while 3 insiders reported sales totaling $6.7M. 3 of 12 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.

Insider transactions

Open-market purchases and sales.

Filed Insider Type Shares Price Value Since Score
Jul 10SEC Sukumar NagendranPresident Sell Plan 200,000936,410 held (−18%) $6.24 $1.2M -28.0% —
Apr 13SEC Sukumar NagendranPresident Sell Plan 200,0001,136,410 held (−15%) $4.46 $892K +0.7% —
Feb 6SEC Kamran AlamCFO Sell 1,6551,442,131 held (−0%) $4.52 $7K -0.7% —
Jan 27SEC Sean P. NolanCEO Sell 136,7892,949,569 held (−4%) $4.75 $650K -5.5% —
Jan 27SEC Sukumar NagendranPresident Sell 89,1321,344,307 held (−6%) $4.75 $423K -5.5% —
Jan 27SEC Kamran AlamCFO Sell 78,9681,467,635 held (−5%) $4.75 $375K -5.5% —
Jan 27SEC Sean P. NolanCEO Sell 41,3122,908,257 held (−1%) $4.61 $190K -2.6% —
Jan 27SEC Sukumar NagendranPresident Sell 26,9181,317,389 held (−2%) $4.61 $124K -2.6% —
Jan 27SEC Kamran AlamCFO Sell 23,8491,443,786 held (−2%) $4.61 $110K -2.6% —
Jan 14SEC Sukumar NagendranPresident Sell Plan 200,0001,006,439 held (−17%) $4.71 $942K -4.7% —
Dec 1SEC Sukumar NagendranPresident Sell 260,0471,006,439 held (−21%) $4.51 $1.2M -0.4% —
Dec 1SEC Sukumar NagendranPresident Sell 110,1251,006,439 held (−10%) $4.75 $523K -5.5% —

Insiders at Taysha Gene Therapies, Inc.

InsiderBoughtSoldLast filingScore
Sukumar NagendranPresident — $5.3M Jul 10, 2026 —
Sean P. NolanCEO — $840K Jan 27, 2026 —
Kamran AlamCFO — $493K Feb 6, 2026 —

TSHA stock: common questions

Are Taysha Gene Therapies, Inc. insiders buying TSHA stock?

In the past 12 months, 0 insiders reported open-market purchases of TSHA worth $0.

Are Taysha Gene Therapies, Inc. insiders selling TSHA stock?

3 insiders reported sales worth $6.7M over the same period.

Where does this data come from?

Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.

What is TSHA's 52-week range?

Over the past year TSHA has traded between $3.83 and $6.98. It last closed at $4.49 on Oct 9, 2026.